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Introduction
Systemic lupus erythematosus, or lupus, is one of the most 
intriguing diseases due to its diverse clinical picture, vari-
able course and in the single patient also its unpredictable 
outcome. Th   e etiopathogenesis of lupus has been studied 
intensively for many years and the disease has long been 
regarded as the prototype autoimmune disease. Th  e 
reason for this is that a large number of diﬀ  erent auto-
antibodies are produced in lupus patients and that most, 
if not all, cells in the immune system seem to be involved 
in the disease process.
Th  e most prominent feature in lupus is an immune 
response to nucleic acid and associated proteins, which 
results in autoantibody production, immune complex 
(IC) formation and organ inﬂ   ammation. In addition, 
most lupus patients display several signs of an increased 
IFNα production, which during the past years has 
attracted much interest regarding the possible role of this 
cytokine in the disease process. Th  is interest has been 
further inspired by the observation that IFNα adminis-
tration to individuals without any autoimmune condition 
can trigger the production of antinuclear autoantibodies, 
and occasionally also a lupus syndrome.
In the present review, the possible reason(s) behind the 
ongoing IFNα production in lupus will be reviewed, as 
well as the role of IFNα in the etiopathogenesis and the 
clinical manifestations of the disease. Th  e potential 
application in clinical practice of our present knowledge 
of the type I interferon system in lupus will also be 
discussed.
IFNα in lupus patients
Th  e  ﬁ  rst described cytokine abnormality in lupus patients 
was an increased serum level of interferon [1], which 
subsequently was characterized as IFNα [2]. Early studies 
also demonstrated that lupus patients have increased 
levels of IFNα-induced proteins, such as 2΄,5΄-adenylate 
synthetase [3] and MxA [4]. Th  e latter report showed 
that >90% of lupus patients displayed increased expres-
sion of MxA, even if measurable serum IFNα levels could 
not be detected. Further studies showed that serum IFNα 
levels correlated to disease activity, but also to signs of 
immune activation and several clinical disease manifes-
tations [5].
Functional analysis of type I interferon activity in 
serum from lupus patients has revealed that there is an 
association between serum interferon activity and 
immuno  logical phenotype [6]. When genome-wide gene 
expression proﬁ   ling became available, several research 
groups observed that a large proportion of lupus patients 
have an increased expression of type I interferon-regu-
lated genes (an interferon signature) in peripheral blood 
Abstract
Patients with lupus have a continuous production 
of IFNα and display an increased expression of IFNα-
regulated genes. The reason for the ongoing IFNα 
synthesis in these patients seems to be an activation 
of plasmacytoid dendritic cells (pDCs) by immune 
complexes (ICs), consisting of autoantibodies in 
combination with DNA-containing or RNA-containing 
autoantigens. The mechanisms behind the activation 
of pDCs by such ICs have to some extent been 
elucidated during the last years. Thus, interferogenic 
ICs are internalized via the FcγRIIa expressed on pDCs, 
reach the endosomes and stimulate Toll-like receptor 
(TLR) 7 or 9, which subsequently leads to IFNα gene 
transcription. Variants of genes involved in both the 
IFNα synthesis and response have been linked to an 
increased risk to develop lupus. Among these genes 
are interferon regulatory factor 5 (IRF5), which is 
involved in TLR signaling, and the signal transducer and 
activator of transcription 4 (STAT4) that interacts with 
the type I interferon receptor. Produced IFNα may at 
least partially be responsible for several of the observed 
alterations in the immune system of lupus patients and 
contribute to the autoimmune disease process, which 
will be discussed in the present review. How produced 
IFNα can contribute to some clinical manifestations 
will briefl  y be described, as well as the possible 
consequences of this knowledge in clinical practice for 
disease monitoring and therapy.
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© 2010 BioMed Central Ltdmononuclear cells [7-10], but also in aﬀ  ected organs such 
as the kidneys [11]. Th   e interferon signature was 
observed in almost all pediatric lupus patients with active 
disease of recent onset [7]; in adults with more long-
lasting and less active disease, in comparison, approxi-
mately one-half of the patients displayed the interferon 
signature [8,9].
Induction of IFNα production in lupus
Th  e natural interferon-producing cell, also termed the 
plasmacytoid dendritic cell (pDC), has the unique 
capacity to secrete up to 109 IFNα molecules per cell in 
response to viral infections [12]. Th   ese cells appear to be 
the major type I interferon-producing cell for many 
diﬀ  erent interferon inducers, including both viruses and 
bacteria. Th  e prominent signs of an ongoing IFNα pro-
duc  tion in lupus therefore raise questions of the natural 
interferon-produ  cing cell/pDC function and the potential 
IFNα inducers in these patients.
Natural interferon-producing cells/plasmacytoid dendritic 
cells
Several studies have shown that the frequency of circu-
lating pDCs is markedly reduced in lupus patients 
[13-15], although residual single cells upon stimulation 
have a normal IFNα-producing capacity. Th  e  reason  for 
the decreased number of circulating pDCs seems to be a 
migration of these cells to tissues, because an increased 
number of pDCs can readily be detected in the skin 
[16,17], in lymph nodes [18] and in renal tissue [19] from 
lupus patients. pDCs are furthermore activated in vivo 
and synthesize IFNα, which indicates that these cells are 
responsible for the continuous IFNα production in lupus.
Th  e pDCs can be activated to IFNα production via 
triggering of Toll-like receptor (TLR) 7 or TLR9, which 
sense single-stranded RNA and CpG-containing DNA, 
respectively (reviewed in [20]). Th  ese receptors are 
localized in the endosome to prevent activation by self 
RNA or DNA. Ligation of the TLRs leads to interaction 
with the myeloid diﬀ  erentiation factor 88 adaptor protein 
and subsequent phosphorylation of several transcription 
factors, among which interferon regulatory factor (IRF) 5 
and IRF7 are most important. In addition, the TLR9-
mediated induction of type I interferon production 
requires an intact mammalian target of rapamycin 
pathway [21].
Inducers of IFNα in lupus
In the search for an endogenous IFNα inducer in lupus, 
we noted that sera from such patients contain ICs 
consisting of autoantibodies and DNA with the capacity 
to speciﬁ   cally activate pDCs [22,23]. Further studies 
revealed that such interferogenic ICs are internalized via 
the FcγRIIa expressed on pDCs [24], reach the endosome 
and stimulate the relevant TLR with subsequent 
activation of transcription factors and IFNα production 
[25]. Th  is mechanism for induction of type I interferon 
production has been demonstrated in vitro for both 
DNA-containing and RNA-containing ICs. Th  e nucleic-
acid-containing autoantigens in the interferogenic ICs 
can be generated from apoptotic or necrotic cells [26], 
which is relevant given the increased apoptosis and 
reduced clearance of apoptotic cells in lupus [27]. Several 
molecules are involved in the IFNα response to these ICs. 
Th  e high-mobility group box 1 protein/receptor for 
advanced glycation end-products interaction is necessary 
for the TLR9-induced IFNα production by DNA-contain-
ing ICs [28], whereas C1q decreases the IFNα production 
by interferogenic ICs [29].
Th  ere exist several diﬀ  erent ICs with the capacity to 
activate pDCs, but RNA-containing ICs that trigger 
TLR7 seem to be especially potent as IFNα inducers 
[30,31]. Th  ere is also a correlation in lupus patients 
between serum IFNα activity and the presence of auto-
antibodies to RNA binding proteins [6]. Such autoanti-
bodies appear very early in the development of the 
disease, usually several years before the appearance of 
clinical overt lupus disease [32]. Since some of these 
autoantibodies show cross-reactivity with viral epitopes, 
the initial trigger for the production of antibodies with 
IFNα inducting capacity could well be a viral infection 
[33]. Th  is scenario would connect viral infections with 
the generation of interferogenic ICs, with the capacity to 
create a self-perpetuating vicious circle driven by IFNα 
[34] (see Figure 1).
Genetic susceptibility
One obvious question is whether certain individuals have 
an enhanced IFNα production or sensitivity, which could 
increase the risk to develop lupus if nucleic-acid-
containing ICs appear. Th   e observation that a high serum 
IFNα activity seems to be a heritable risk factor for lupus 
[35] indicates that the genetic control of the type I 
interferon system is important for the risk to develop this 
disease (for a comprehensive review, see article S3 in this 
supplement).
Th  e transcription factor IRF5, which is constitutively 
expressed in pDCs [36], was the ﬁ  rst  identiﬁ  ed  gene 
directly involved in IFNα production that was associated 
with increased risk for lupus [37]. Th   e allele variants with 
the highest probability of being causal were identiﬁ  ed 
recently, and were shown to aﬀ  ect the IRF5 expression, 
which is increased in peripheral blood mononuclear cells 
from lupus patients [38]. An IRF5 risk haplotype is 
associated with a high serum IFNα activity in patients, and 
especially in those with autoantibodies to RNA bind  ing 
proteins or double-stranded DNA [39], linking lupus 
genetic susceptibility to the presence of interferogenic ICs.
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in TLR signaling and IFNα production, is also associated 
with lupus [40], which further strengthens the view that 
the genetic control of the IFNα production is important 
for the risk to develop lupus. Th   e importance of the TLR 
pathways in this disease is further underscored by the 
observations that gene variants of the TNFα-induced 
protein 3 is associated with increased risk for lupus [41,42].
Among genes involved in the response to IFNα, the 
signal transducer and activator of transcription 4 (STAT4) 
that interacts with the cytoplasmic part of the type I 
interferon receptor (IFNAR) [43] is strongly associated 
Figure 1. Role of the type I interferon system in the etiopathogenesis of lupus. A viral infection induces IFNα production in plasmacytoid 
dendritic cells (pDCs) and the release of autoantigens from dying cells. Produced IFNα promotes maturation of monocytes to dendritic cells, 
activation of T cells and stimulation of B cells, as described in the text. In individuals with a genetic set-up that causes a strong IFNα production and/
or a marked IFNα response, tolerance is broken and antibodies against nucleic-acid-containing autoantigens are produced. The autoantibodies, 
together with the autoantigens, form interferogenic immune complexes (ICs) that act as endogenous inducers of IFNα production in pDCs. In 
addition, these ICs can directly stimulate the B cells to increased autoantibody production. UV-light induced apoptosis will increase the release 
of autoantigens, which will result in the formation of more interferogenic ICs. All these events will establish a vicious circle with an ongoing 
production of IFNα by the pDCs and a continuous exposure of the immune system to IFNα that maintains the autoimmune process. Natural killer 
(NK) cells promote the IFNα production, and activated monocytes downregulate the NK cells, but the monocyte function seems to be defi  cient in 
lupus. Figure modifi  ed from [87]. DC, dendritic cell; Mo, monocyte; TCR, T-cell receptor.
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Page 3 of 8with lupus [44]. In lupus patients there is an association 
between the STAT4 genotype, increased sensitivity to 
IFNα [45] and a more severe phenotype, which includes 
nephritis and the presence of anti-double-stranded DNA 
autoantibodies [46,47]. Polymorphisms in the Janus 
kinase tyrosine kinase 2, which binds to the IFNAR and is 
required for signaling through this receptor, is also 
associated with lupus [37,48].
Th   ese data provide further evidence for a link between 
the IFNα response and the disease process in lupus. 
Additional susceptibility genes for lupus can be involved 
in the activation of the type I interferon system by other 
mechanisms – for instance, via increased production of 
autoantibodies and subsequent generation of more 
interferogenic ICs [49].
Consequences of the ongoing IFNα production in 
lupus
What are the consequences of the ongoing IFNα synthesis 
in lupus patients? Produced IFNα will aﬀ  ect most cells in 
the immune system and can therefore stimulate the central 
autoimmune process, but IFNα will also contribute to the 
expression of some clinical signs and symptoms.
IFNα and autoimmunity
Th  e possible role of IFNα as an inducer of lupus was 
originally suggested by the observation that the adminis-
tration of IFNα to a patient with a malignant disease 
induced a lupus syndrome indistinguishable from naturally 
occurring lupus [50]. During the years, many reports 
have described the induction of several diﬀ  erent auto-
immune diseases during prolonged treatment of patients 
with IFNα [51]. Th   e presence of autoantibodies in patient 
sera before the onset of IFNα therapy considerably 
increases the risk for development of clinical overt 
autoimmune disease during IFNα administration [52]. 
Th  ese observations demonstrate that IFNα has the 
capacity to both break the tolerance and enhance a 
smoldering autoimmune process.
Th   e mechanisms behind the pro-autoimmune eﬀ  ects of 
IFNα are not clear, but there exist several possibilities. 
First, IFNα can induce increased expression of auto-
antigens, such as Ro52 [7,8], but can also promote the 
release of autoantigens by induction of apoptosis [53]. 
Secondly, IFNα has multiple eﬀ  ects in both the innate 
and adaptive immune systems, which best can be 
described as a general activation of the immune cells. 
IFNα thus induces dendritic cell maturation and activa-
tion, with increased expression of MHC class I and II 
molecules, chemokines and chemokine receptors, 
costimu  latory molecules such as CD80, CD86, the 
B-lymphocyte stimulator and a proliferation-inducing 
ligand [54]. Importantly, IFNα can also induce the 
expression of TLR7 [55], which may enhance the 
responsive  ness to interferogenic ICs. Th   e development of 
helper T cells along the T-helper type 1 pathway is 
promoted, and cytotoxic T cells are stimulated by type I 
interferons, due to an increase in dendritic cell cross-
presentation, inhibition of T-cell apoptosis as well as 
stimulation of IL-2 secretion by central memory T cells 
[56]. Type I interferons cause B-cell activation, diﬀ  eren-
tia  tion, antibody production and immunoglobulin isotype 
class switching [57,58], but can also decrease the 
selectivity of B cells for CpG-rich DNA and allow 
stimulation by even non-CpG DNA [59] – thereby 
promot  ing an autoimmune response. Consequently, 
several IFNα-mediated eﬀ  ects can contribute to the auto-
immune process in the pathogenesis of lupus. Figure 1 
shows a schematic view of the possible role of IFNα in 
the disease process.
IFNα production is aﬀ  ected by several cytokines and 
cells in the immune system. TNFα and IL-10 can down-
regulate the IC-mediated IFNα produc  tion [60], and 
TNFα also inhibits the generation of pDCs [61]. Th  e 
IFNα response is furthermore regulated by several cells 
in the immune system, such as natural killer cells and 
monocytes. Natural killer cells promote the IFNα 
production whereas the monocytes downregulate the 
type I IFNα response, and this control mechanism may 
be deﬁ  cient in lupus patients [62]. Th  e complex inter-
action between the diﬀ  erent cytokines and the immune 
system in lupus patients may be further clariﬁ  ed by a 
network-based analysis of abnormally regulated genes in 
these patients [63].
IFNα and disease manifestation
Several observations suggest that IFNα may have an 
important role in some of the clinical manifestations in 
lupus patients. Th   ere is an association between increased 
serum levels of IFNα and fever, skin rash and leucopenia 
[5], which perhaps is not surprising considering these 
symptoms are commonly seen during viral infections. 
Among the more speciﬁ  c lupus manifestations, an early 
study observed that patients with lupus psychosis have 
detectable levels of IFNα in the c    erebrospinal ﬂ  uid [64], 
which is intriguing given the observed neuropsychiatric 
adverse eﬀ   ects during IFNα treatment [65]. Recently, 
auto  antibodies with the ability to form very potent inter-
ferogenic ICs together with RNA-containing auto-
antigens were demonstrated in the cerebrospinal ﬂ  uid of 
lupus patients with neuropsychiatric manifestations [66]. 
Th  ese ICs also induced other chemokines and pro-
inﬂ   ammatory cytokines of possible relevance for the 
central nervous system manifestations frequently seen in 
lupus, which indicates that the interferogenic ICs may be 
directly involved in central nervous system lupus.
Results from an experimental model suggest that IFNα 
can drive the nephritis and end organ damage in lupus 
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active human lupus nephritis [19]. Th  ese observations 
are in line with the ﬁ  ndings that major organ involvement 
in lupus patients, including nephritis, is connected to a 
more pronounced IFNα signature [8] and that IFNα-
regulated genes are overexpressed in the glomeruli from 
lupus nephritis [11]. Th   e role of IFNα in the premature 
atherosclerosis typically seen in lupus patients is unclear, 
but IFNα may contribute to the atherosclerotic process 
by impairing endothelial cell diﬀ  erentiation [68]. Further-
more, pDCs are present in atherosclerotic plaques from 
carotid lesions where, via produced IFNα, they can act as 
inﬂ  ammatory ampliﬁ  ers and destabilize the plaque [69].
IFNα in clinical practice
We are at the beginning of an era were the basic 
knowledge of the type I interferon system in lupus is 
translated into clinical useful tools for monitoring and 
treating patients.
IFNα as a biomarker
Th   ere is a correlation between the serum levels of IFNα 
and disease activity in lupus patients, as mentioned 
above. Owing to diﬃ   culties in measuring IFNα in serum, 
however, most investigators study the interferon 
signature as a potential biomarker. A more pronounced 
inter  feron signature is seen in patients with active disease 
and major disease manifestations, such as nephritis, 
cerebritis, hematological manifestations and increased 
damage index [7,8,70-72]. Administration of high doses 
of corticosteroids to lupus patients with active disease, 
which induces clinical remission, will normalize the 
interferon signature [7]. Th   ese observations have demon-
strated a connection between the IFNα signature and the 
clinical status of the patients. Whether determination of 
the interferon-induced gene expression can be used to 
closely monitor the disease activity in single patients 
during longitudinal follow-up is uncertain, however, 
because the interferon signature seems to remain stable 
in the patients despite changes in disease activity [72,73]. 
On the other hand, two preliminary reports have 
suggested that the interferon-gene proﬁ  le of peripheral 
blood cells could predict future disease activity [74,75].
At the moment, the clinical value of monitoring the 
IFNα signature during long-term follow-up remains to be 
established. Two other approaches to follow disease 
activity are either to look at expression of type I 
interferon-regulated molecules on cells involved in the 
disease process, such as Siglec-1 on monocytes [76], or to 
measure the level of interferon-regulated chemokines 
[77]. Interestingly, the interferon-regulated chemokines 
may also be connected to organ damage [78].
Th   ere is also a possibility that genes within the type I 
interferon signaling pathway can be used as biomarkers 
for organ involvement and severity. Th  ere is thus an 
association between the STAT4 genotype and risk for a 
more severe disease phenotype that includes nephritis 
[46,47] and stroke [79]. Th   e latter observation is interest-
ing, because the association between a STAT4 risk variant 
and stroke was of the same magnitude as the association 
between stroke and hypertension, indicating that auto-
immune processes may be very important for many 
disease manifestations in lupus, even those that 
traditionally not are regarded as autoimmune. Further-
more, a combination of risk alleles within the type I inter-
feron signaling pathway dramatically increases the risk 
for lupus [47], which illustrates how genetic mapping in 
the future perhaps could aid in the prediction of risk for 
disease.
IFNα as a therapeutic target
Because many observations indicate a crucial role for the 
type I interferon system and IFNα in the etiology and 
pathogenesis of human lupus, several companies are 
developing therapies aiming to inhibit the type I inter-
feron production or eﬀ  ects in the disease. Th  is  develop-
ment has been stimulated by the fact that type I IFNAR-
knockout murine lupus models have a reduced disease 
activity [80,81].
Results from the ﬁ  rst phase I clinical trial using a single 
injection of anti-IFNα monoclonal antibodies in lupus 
patients were recently reported [82,83]. Th  e anti-IFNα 
treatment caused a dose-dependent inhibition of the type 
I interferon inducible genes in both peripheral blood and 
skin biopsies, as well a reduction in clinical disease 
activity. In addition, granulocyte–macrophage colony-
stimulating factor, TNFα, IL-10 and IL-1β inducible gene 
signatures, as well as B-cell activating factor mRNA 
expression, were neutralized in some patients [83] – 
demonstrating the interaction between the type I 
interferon system and other proinﬂ  ammatory pathways. 
Th  e observation that a single injection of an anti-IFNα 
antibody could give a sustained neutralization of the 
interferon signature is of particular interest, and supports 
the view that the ongoing production of interferon in 
lupus is at least partly a result of a self-perpetuating 
vicious circle [34] (Figure 1). No increase in serious viral 
infections has so far been reported among anti-IFNα-
treated patients, which could be due to the fact that 
besides IFNα there exist several other type I interferons 
with strong antiviral activity [84]. Whether these latter 
type I interferons are suﬃ   cient potent to protect anti-
IFNα-treated lupus patients from serious complications 
during, for instance, a ﬂ  u pandemic remains to be estab-
lished, and can only be addressed in larger clinical trials.
Th  ere exist other possible therapeutic targets within 
the type I interferon system, such as the IFNAR, the 
BDCA-2 antigen on pDC [14,85] or oligodeoxyribo-
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None of these agents have so far been tested in human 
lupus patients.
In conclusion, the type I interferon system is activated 
in lupus patients with ongoing IFNα production, which is 
of major importance for the disease process. Th  e  genetic 
and immunological background to this overproduction 
of IFNα is to some extent clariﬁ  ed, but several questions 
still remain to be answered. Despite this, several studies 
aiming to target the increased IFNα levels or its eﬀ  ects in 
lupus patients are planned, or are in the early clinical 
phase. Th   ese treatment regimes will hopefully bring relief 
to our patients without interfering with the normal 
function of the type I interferon system.
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